Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| HM14062 | Other Identifier | Virginia Commonwealth Unniversity IRB |
Not provided
Not provided
Not provided
Slow accrual
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This clinical trial studies dietary and exercise interventions in preventing cardiovascular disease in younger survivors of childhood cancer. Eating a healthy diet and exercising regularly may reduce the risk of cardiovascular disease in younger survivors of childhood cancer.
Participants receive personalized exercise plan and prescription tailored to individual needs and current level of activity and fitness, and they also receive 2 one-hour individual exercise training sessions consisting of 20-30 minutes cardiovascular activity and strength training. Participants receive nutritional education consisting of energy balance, appropriate portion sizes, calorie count, and basic nutrition skills such as label reading every 2 weeks for 12 weeks.
After completion of study treatment, patients are followed for up to 6 months.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Specimen Collection/Risk Factor Assessment -> Diet/Exercise -> | Experimental | Specimen Collection/Risk Factor Assessment -> Diet/Exercise -> Chemotherapy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Specimen Collection/Risk Factor Assessment -> Diet/Exercise -> Chemotherapy | Behavioral | Participants will be taught by a registered dietician about energy balance and how body weight relates to energy intake and expenditure, although specific calorie prescriptions will not be given. An exercise physiologist will create a personalized exercise plan and prescription which is tailored to his / her needs and current level of activity and fitness |
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility determined by average attendance and retention | Acceptability will be determined by responses on feedback measures and qualitative analysis of exit interviews. | At 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility determined by average attendance and retention from the blood pressure at enrollment | Will be assessed via paired T test. | At 6 months |
| Acceptability level at time of enrollment | Acceptability will be determined by responses on feedback measures and qualitative analysis of exit interviews. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Marieka A Helou, MD | Massey Cancer Center | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| At 6 months |
| ID | Term |
|---|---|
| D009369 | Neoplasms |
| D006689 | Hodgkin Disease |
| D009461 | Neurologic Manifestations |
| D008228 | Lymphoma, Non-Hodgkin |
| D007938 | Leukemia |
| ID | Term |
|---|---|
| D008223 | Lymphoma |
| D009370 | Neoplasms by Histologic Type |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D006402 | Hematologic Diseases |
Not provided
Not provided